69430人已查看 《Asian Pacific Journal of Cancer Prevention》 期刊2024最新IF预测值
预警说明查看说明
时间
预警情况
2024年02月发布的2024版
不在预警名单中
2023年01月发布的2023版
不在预警名单中
2021年12月发布的2021版
不在预警名单中
2020年12月发布的2020版
不在预警名单中
2025年预警名单预测
无异常数据 期刊预警概率很低
结果仅供参考
*来源:中科院《 国际期刊预警名单》
中科院分区查看说明
版本
大类学科
小类学科
Top期刊
综述期刊
暂无数据
JCR分区
WOS分区等级:Q0区
版本
按学科
分区
WOS期刊SCI分区
WOS期刊SCI分区
WOS期刊SCI分区是指SCI官方(Web of
Science)为每个学科内的期刊按照IF数值排序,将期刊按照四等分的方法划分的Q1-Q4等级,Q1代表质量最高,即常说的1区期刊。
(2022-2023年最新版)
暂无数据
暂无数据
测一测你投这本期刊的成功率
【官方推荐】国内首个期刊投稿预测系统,多维度分析投稿成功率,助你精准决策
12498
人已预测
期刊介绍
Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation.The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally. The APJCP publishes original research results under the following categories:-Epidemiology, detection and screening.-Cellular research and bio-markers.-Identification of bio-targets and agents with novel mechanisms of action.-Optimal clinical use of existing anti-cancer agents, including combination therapies.-Radiation and surgery.-Palliative care.-Patient adherence, quality of life, satisfaction.-Health economic evaluations.